NZ707477A - Activin-actrii antagonists and uses for treating bone and other disorders - Google Patents

Activin-actrii antagonists and uses for treating bone and other disorders

Info

Publication number
NZ707477A
NZ707477A NZ70747713A NZ70747713A NZ707477A NZ 707477 A NZ707477 A NZ 707477A NZ 70747713 A NZ70747713 A NZ 70747713A NZ 70747713 A NZ70747713 A NZ 70747713A NZ 707477 A NZ707477 A NZ 707477A
Authority
NZ
New Zealand
Prior art keywords
activin
treatment
disorders
treating bone
bone disorders
Prior art date
Application number
NZ70747713A
Other languages
English (en)
Inventor
Victor Sloan
Keith Hruska
Yifu Fang
Randall Stevens
William Smith
Victoria Sung
Original Assignee
Celgene Corp
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Univ Washington filed Critical Celgene Corp
Priority to NZ747422A priority Critical patent/NZ747422B2/en
Publication of NZ707477A publication Critical patent/NZ707477A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ70747713A 2012-11-02 2013-11-01 Activin-actrii antagonists and uses for treating bone and other disorders NZ707477A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ747422A NZ747422B2 (en) 2012-11-02 2013-11-01 Activin-actrii antagonists and uses for treating bone and other disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261721898P 2012-11-02 2012-11-02
US201261740665P 2012-12-21 2012-12-21
PCT/US2013/068009 WO2014071158A1 (en) 2012-11-02 2013-11-01 Activin-actrii antagonists and uses for treating bone and other disorders

Publications (1)

Publication Number Publication Date
NZ707477A true NZ707477A (en) 2019-09-27

Family

ID=50628091

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ70747713A NZ707477A (en) 2012-11-02 2013-11-01 Activin-actrii antagonists and uses for treating bone and other disorders

Country Status (15)

Country Link
US (3) US10195249B2 (OSRAM)
EP (3) EP3308796B1 (OSRAM)
JP (4) JP2016504275A (OSRAM)
KR (3) KR20210091358A (OSRAM)
CN (1) CN104936605A (OSRAM)
AU (3) AU2013337677B2 (OSRAM)
BR (1) BR112015009948B1 (OSRAM)
CA (2) CA3120678A1 (OSRAM)
ES (2) ES2652437T3 (OSRAM)
IL (2) IL238443B (OSRAM)
MX (2) MX366336B (OSRAM)
NZ (1) NZ707477A (OSRAM)
RU (2) RU2018145985A (OSRAM)
WO (1) WO2014071158A1 (OSRAM)
ZA (1) ZA201503135B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
CA2986432A1 (en) 2015-05-20 2016-11-24 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
WO2017176938A1 (en) * 2016-04-06 2017-10-12 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
SI3496739T1 (sl) * 2016-07-15 2021-06-30 Acceleron Pharma Inc. Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
CN110198743B (zh) * 2016-10-05 2023-07-18 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
JP7097354B2 (ja) 2016-10-05 2022-07-07 アクセルロン ファーマ インコーポレイテッド Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
JP7339159B2 (ja) 2017-03-24 2023-09-05 ノバルティス アーゲー 心疾患の予防および治療方法
CN107320718B (zh) * 2017-05-23 2020-12-11 余红 促生长激素释放激素激动剂在制备抗血管钙化药物中的应用
US12168683B2 (en) 2018-05-03 2024-12-17 Acceleron Pharma Inc. Binders of TGFβ-superfamily ligands and uses thereof
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4387647A4 (en) * 2021-08-16 2025-05-14 Acceleron Pharma, Inc. COMPOSITIONS AND METHODS FOR TREATING KIDNEY DISEASE OR CONDITION

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4973577A (en) 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
AU8761391A (en) 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
US6162896A (en) 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US5885794A (en) 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
KR100255415B1 (ko) 1991-06-25 2000-05-01 브루스 엠. 에이센 비엠피-9 조성물
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP0679163A4 (en) 1993-01-12 1997-07-16 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-3.
JPH09501305A (ja) 1993-05-12 1997-02-10 ジェネティックス・インスティテュート・インコーポレイテッド Ｂｍｐ−１０組成物
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
CA2174098C (en) 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US6132988A (en) 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US20050244867A1 (en) 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
CZ130199A3 (cs) 1996-10-25 1999-07-14 G. D. Searle & Co. Cirkulárně permutovaní agonisté receptoru erythropoietinu
US6605699B1 (en) 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999010364A1 (en) 1997-08-29 1999-03-04 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
CN1277632A (zh) 1997-10-03 2000-12-20 中外制药株式会社 天然人源化抗体
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
EP1113799A4 (en) 1998-09-17 2004-06-09 Lilly Co Eli PROTEIN-BASED PREPARATION
WO2000017350A1 (fr) 1998-09-22 2000-03-30 Long Yu Sequence codante pour un nouveau facteur de differenciation de la croissance d'origine humaine et polypeptide code par cette sequence d'adn, et methode de production correspondante
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1174149A1 (en) 1999-04-19 2002-01-23 Kyowa Hakko Kogyo Co., Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
HUP0203409A3 (en) 1999-11-12 2005-06-28 Maxygen Holdings Ltd Redwood C Interferon gamma conjugates
ATE319470T1 (de) 1999-12-15 2006-03-15 Res Dev Foundation Betaglycan als ein inhibin rezeptor und dessen verwendung
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
PL219131B1 (pl) 2000-05-15 2015-03-31 Hoffmann La Roche Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
AU2001269709A1 (en) 2000-07-19 2002-02-05 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
JP2004526419A (ja) 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CA2429473C (en) 2000-11-20 2011-02-15 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
EP1370287A2 (en) 2000-12-01 2003-12-17 Wyeth Method and composition for modulating bone growth
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20040132675A1 (en) 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
WO2002074340A1 (fr) 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
ATE446771T1 (de) 2001-05-24 2009-11-15 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
JP2005508141A (ja) 2001-05-25 2005-03-31 セローノ ジェネティクス インスティテュート ソシエテ アニニム ヒトｃＤＮＡおよびタンパク質、ならびにそれらの使用
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
KR100912852B1 (ko) 2001-07-17 2009-08-18 데이진 가부시키가이샤 ＰＰＡＲ δ활성화 작용을 측정하는 것을 특징으로 하는물질의 선택방법 및 약제
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
JP2005524612A (ja) 2001-12-06 2005-08-18 ファイブローゲン、インコーポレーテッド 内因性エリスロポエチン（ｅｐｏ）を増加させる方法
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
KR20040082421A (ko) 2002-02-11 2004-09-24 제넨테크, 인크. 빠른 항원 결합 속도를 갖는 항체 변이체
AU2003217612A1 (en) 2002-02-21 2003-09-09 Wyeth GASP1: a follistatin domain containing protein
AU2003216345A1 (en) 2002-02-21 2003-09-09 Wyeth Follistatin domain containing proteins
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
WO2004016639A1 (en) 2002-08-16 2004-02-26 Wyeth Bmp-2 estrogen responsive element and methods of using the same
BR0315316A (pt) 2002-10-15 2005-08-16 Celgene Corp Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2004064770A2 (en) 2003-01-17 2004-08-05 Government Of The United States Of America As Represented By The Secretary, Department Of Health Andhuman Services Use of smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
CN100427081C (zh) 2003-02-07 2008-10-22 普罗米蒂克生物科学公司 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物
US20040197828A1 (en) 2003-03-26 2004-10-07 Gaddy Dana P. Method for diagnosis and treatment of bone turnover
WO2010019832A2 (en) 2008-08-13 2010-02-18 Designer Molecules, Inc. Amide-extended crosslinking compounds and methods for use thereof
WO2005028517A2 (en) 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US7611465B2 (en) 2003-07-15 2009-11-03 Board Of Regents, The University Of Texas System Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
DE10335211A1 (de) 2003-08-01 2005-02-17 Robert Bosch Gmbh Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
US20070135336A1 (en) 2003-09-15 2007-06-14 De Kretser David Follistatin isoforms and uses thereof
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
DK1706428T3 (da) 2004-01-22 2009-11-30 Merck Patent Gmbh Anti-cancer-antistoffer med reduceret komplementfiksering
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2005094871A2 (en) 2004-03-26 2005-10-13 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
JP2008500816A (ja) 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
US7741284B2 (en) 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
AU2005258286A1 (en) 2004-06-24 2006-01-05 Acceleron Pharma Inc. GDF3 propeptides and related methods
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
EP1794191B1 (en) 2004-08-05 2016-05-18 The Regents of The University of California Molecules with effects on cellular development and function
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
WO2006039400A2 (en) 2004-09-29 2006-04-13 Mount Sinai School Of Medicine Of New York University Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
WO2006052842A2 (en) 2004-11-09 2006-05-18 The Trustees Of The University Of Pennsylvania Methods for diagnosis of myelodysplastic syndromes (mds)
WO2006055689A2 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
ES2547866T3 (es) 2005-02-16 2015-10-09 The General Hospital Corporation Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina
CN101198321A (zh) 2005-04-26 2008-06-11 味之素株式会社 骨髓祖红细胞分化诱导剂
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
DK1931697T3 (da) 2005-09-28 2010-11-08 Zymogenetics Inc IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2006321906C1 (en) 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
EP1966183A4 (en) 2005-12-20 2010-12-29 Merck Frosst Canada Ltd HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
EP1973909A2 (en) 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
US7361510B2 (en) 2006-01-20 2008-04-22 Beckman Coulter, Inc. Methods of detection of iron deficiency
CA2637375A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007101060A2 (en) 2006-02-28 2007-09-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8008074B2 (en) * 2006-03-20 2011-08-30 The Uab Research Foundation Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
EP2007813A2 (en) 2006-04-14 2008-12-31 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
CN101522021B (zh) 2006-07-21 2014-07-30 莱因实验室 醋酸钙的液体组合物
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP5468187B2 (ja) 2006-09-26 2014-04-09 ポリプラスチックス株式会社 ポリアセタール樹脂組成物
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
AU2007332473B2 (en) 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
UA116871C2 (uk) * 2006-12-18 2018-05-25 Акселерон Фарма Інк. СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
CA2685306A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
PT2170396T (pt) 2007-08-03 2017-03-31 Summit Corp Plc Combinação de fármacos para o tratamento da distrofia muscular de duchenne
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
US20100279409A1 (en) 2007-09-13 2010-11-04 Neil Robson Method for modifying celluar immune resonse by modulating activin activity
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8043620B2 (en) 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
WO2009146148A2 (en) 2008-04-04 2009-12-03 Tactair Fluid Controls, Inc. Locking mechanism with bi-modal actuator
US20110104133A1 (en) 2008-05-06 2011-05-05 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
WO2009146408A1 (en) 2008-05-30 2009-12-03 Summa Health Systems Llc Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
CA2729096C (en) * 2008-06-26 2020-04-28 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
EP2318028B1 (en) 2008-06-26 2020-02-19 Acceleron Pharma Inc. Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
CA2997971A1 (en) 2008-11-26 2010-06-03 Amgen Inc. Variants of activin iib receptor polypeptides and uses thereof
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
CA2750559A1 (en) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
US20100267731A1 (en) 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2844123T3 (es) 2009-08-13 2021-07-21 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
MX340451B (es) 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
DK2726099T3 (en) 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
CN107837390A (zh) 2011-10-17 2018-03-27 阿塞勒隆制药公司 用于治疗无效性红细胞生成的方法和组合物
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
EP2771017A4 (en) 2011-10-28 2015-04-01 Paranta Biosciences Ltd METHOD FOR THE TREATMENT OF SLIP SEED SECRETION
AU2012364736A1 (en) 2011-12-19 2014-07-24 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
WO2013148277A1 (en) 2012-03-30 2013-10-03 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP3521310A1 (en) 2012-06-14 2019-08-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
CA2874117C (en) 2012-07-02 2021-10-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
EP2912462B1 (en) 2012-10-24 2019-08-07 Celgene Corporation Biomarker for use in treating anemia
EP2911682A4 (en) 2012-10-24 2016-03-23 Celgene Corp METHOD FOR TREATING ANEMIA
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
ES3023054T3 (en) 2012-11-08 2025-05-29 Clearside Biomedical Inc Methods for the treatment of ocular disease in human subjects
CN103047581B (zh) 2012-12-04 2015-04-01 京东方科技集团股份有限公司 背光模组及具有该背光模组的显示装置
US20150328249A1 (en) 2012-12-11 2015-11-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
WO2015089575A1 (en) 2013-12-16 2015-06-25 Paranta Biosciences Limited Method of diagnosis and treatment
EP3094751A4 (en) 2014-01-14 2017-06-07 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
JP2017510622A (ja) 2014-01-27 2017-04-13 ノバルティス アーゲー 筋萎縮を予測するバイオマーカー、方法および使用
KR102520970B1 (ko) 2014-03-21 2023-04-12 악셀레론 파마 인코포레이티드 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
EP3808778A1 (en) 2014-04-18 2021-04-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
KR20170035891A (ko) 2014-06-13 2017-03-31 산타 마리아 바이오테라퓨틱스, 인코포레이티드 제형화된 수용체 폴리펩타이드 및 관련 방법
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
AU2016261913B2 (en) 2015-05-13 2021-08-12 Acceleron Pharma Inc. Treatment of beta-thalassemia using ActRII ligand traps
CA2986432A1 (en) 2015-05-20 2016-11-24 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10550170B2 (en) 2015-11-23 2020-02-04 Acceleron Pharma Inc. Methods for treating vascular eye disorders with actrii antagonists
AU2017302282B2 (en) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Methods and compositions for treating myelofibrosis

Also Published As

Publication number Publication date
MX2019008085A (es) 2019-09-09
CA2890217C (en) 2021-07-20
BR112015009948A8 (pt) 2021-10-19
RU2678117C2 (ru) 2019-01-23
EP2914277B1 (en) 2017-09-13
CN104936605A (zh) 2015-09-23
US20190262423A1 (en) 2019-08-29
JP6714646B2 (ja) 2020-06-24
ZA201503135B (en) 2019-09-25
KR102279522B1 (ko) 2021-07-19
NZ747422A (en) 2021-04-30
KR20220156979A (ko) 2022-11-28
US20150283209A1 (en) 2015-10-08
AU2020213397A1 (en) 2020-08-27
KR20150082423A (ko) 2015-07-15
JP2018168176A (ja) 2018-11-01
BR112015009948A2 (pt) 2017-07-11
ES2652437T3 (es) 2018-02-02
AU2013337677B2 (en) 2018-06-28
HK1214525A1 (en) 2016-07-29
IL267066B (en) 2022-02-01
US20230293634A1 (en) 2023-09-21
MX2015005538A (es) 2016-02-05
BR112015009948B1 (pt) 2022-12-06
AU2013337677A1 (en) 2015-05-21
HK1254086A1 (en) 2019-07-12
US10195249B2 (en) 2019-02-05
IL238443A0 (en) 2015-06-30
JP2020143164A (ja) 2020-09-10
EP3308796A1 (en) 2018-04-18
AU2018236696A1 (en) 2018-10-18
RU2015120804A (ru) 2016-12-27
WO2014071158A1 (en) 2014-05-08
EP3964224A1 (en) 2022-03-09
EP2914277A4 (en) 2016-05-25
JP2016504275A (ja) 2016-02-12
ES2884095T3 (es) 2021-12-10
KR20210091358A (ko) 2021-07-21
CA2890217A1 (en) 2014-05-08
EP3308796B1 (en) 2021-07-14
MX366336B (es) 2019-07-05
JP2023011741A (ja) 2023-01-24
IL238443B (en) 2019-07-31
EP2914277A1 (en) 2015-09-09
RU2018145985A (ru) 2019-02-18
MX389254B (es) 2025-03-20
IL267066A (en) 2019-08-29
CA3120678A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
NZ707477A (en) Activin-actrii antagonists and uses for treating bone and other disorders
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
IN2014DN09434A (OSRAM)
AU2011328009A8 (en) Compounds and methods for treating pain
HK1210599A1 (en) Abuse deterrent pharmaceutical compositions for controlled release
PH12016500862A1 (en) Autotaxin inhibitor compounds
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
WO2012125981A3 (en) Raf kinase inhibitors
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
MX2013011421A (es) Derivados de pirazolo-pirimidina.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: WASHINGTON UNIVERSITY ONE BROOKINGS DRIVEST. L, US

Effective date: 20181115

Owner name: CELGENE CORPORATION, US

Effective date: 20181115

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 NOV 2021 BY CPA GLOBAL

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 NOV 2022 BY CPA GLOBAL

Effective date: 20210930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 NOV 2023 BY CPA GLOBAL

Effective date: 20220930

LAPS Patent lapsed